Laptseva Natallia, Rossi Valentina A, Sudano Isabella, Schwotzer Rahel, Ruschitzka Frank, Flammer Andreas J, Duru Firat
Division of Heart Failure, Clinic for Cardiology, University Heart Center Zurich, 8091 Zurich, Switzerland.
Amyloidosis Network Zurich, University Hospital Zurich, 8091 Zurich, Switzerland.
J Clin Med. 2023 Mar 29;12(7):2581. doi: 10.3390/jcm12072581.
Amyloidosis is a systemic disease characterized by extracellular deposits of insoluble amyloid in various tissues and organs. Cardiac amyloidosis is a frequent feature of the disease, causing a progressive, restrictive type of cardiomyopathy, and is associated with adverse clinical outcomes and increased mortality. The typical clinical presentation in patients with cardiac amyloidosis is heart failure (HF) with preserved ejection fraction. Most patients present with typical symptoms and signs of HF, such as exertional dyspnea, pretibial edema, pleural effusions and angina pectoris due to microcirculatory dysfunction. However, patients may also frequently encounter various arrhythmias, such as atrioventricular nodal block, atrial fibrillation and ventricular tachyarrhythmias. The management of arrhythmias in cardiac amyloidosis patients with drugs and devices is often a clinical challenge. Moreover, predictors of life-threatening arrhythmic events are not well defined. This review intends to give a deepened insight into the arrhythmic features of cardiac amyloidosis by discussing the pathogenesis of these arrhythmias, addressing the challenges in risk stratification and strategies for management in these patients.
淀粉样变性是一种全身性疾病,其特征是在各种组织和器官中存在不溶性淀粉样蛋白的细胞外沉积。心脏淀粉样变性是该疾病的常见特征,可导致进行性限制性心肌病,并与不良临床结局和死亡率增加相关。心脏淀粉样变性患者的典型临床表现是射血分数保留的心力衰竭(HF)。大多数患者表现出典型的HF症状和体征,如劳力性呼吸困难、胫前水肿、胸腔积液以及由于微循环功能障碍导致的心绞痛。然而,患者也可能经常出现各种心律失常,如房室传导阻滞、心房颤动和室性快速性心律失常。使用药物和器械对心脏淀粉样变性患者的心律失常进行管理往往是一项临床挑战。此外,危及生命的心律失常事件的预测因素尚不明确。本综述旨在通过讨论这些心律失常的发病机制,探讨这些患者风险分层的挑战以及管理策略,深入了解心脏淀粉样变性的心律失常特征。